This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Investors: Mark Your Calendars, Redux

Successful biotech investors keep a close eye on the calendar. Regulatory decisions and clinical trial results move this sector, so it's important to stay on top of these events whenever possible.

To help readers, I've put together another list of biotech catalyst events for the remainder of this year and the beginning of 2005. This calendar builds upon a similar list I put together in September. Judging by the large volume of email I received after that column was published, a biotech calendar is something a lot of people find extremely valuable.

In the interest of brevity, I've kept descriptions here to a minimum, but I'll likely cover many of these events in more detail in the future.

FDA Approval Decision Dates:

  • Biogen Idec (BIIB) and Elan (ELN): Antegren, multiple sclerosis, Nov. 25;
  • SuperGen (SUPG): Orathecin, pancreatic cancer, Nov. 26;
  • United Therapeutics (UTHR): Remodulin (intravenous formulation), pulmonary arterial hypertension, Nov. 30;
  • Sepracor (SEPR): Estorra, insomnia, Dec. 15;
  • Eyetech Pharmaceuticals (EYET) and Pfizer (PFE): Macugen, age-related macular degeneration, Dec. 17;
  • Genzyme (GENZ) and Bioenvision (BIVN), Clofarabine, acute pediatric leukemia, Dec. 30;
  • OSI Pharmaceuticals (OSIP) and Genentech (DNA): Tarceva, non-small-cell lung cancer, Jan. 30, 2005. (OSI has said it expects approval decision to come earlier than Jan. 30, but the company is not any more specific.);
  • American Pharmaceutical Partners (APPX): Abraxane, breast cancer, Jan. 8, 2005;
  • Cyberonics (CYBX): VNS Therapy System, depression, Jan. 31, 2005;
  • Discovery Labs (DSCO): Surfaxin, respiratory distress syndrome (pediatrics), Feb. 13, 2005;
  • Amylin Pharmaceuticals (AMLN): Symlin, diabetes, March 20, 2005. Exenatide, diabetes, April 30, 2005;
  • Adolor (ADLR): Entereg, post-operative ileus, April 25, 2005.
  • Clinical Data:

  • Celgene (CELG): Revlimid, myelodysplastic syndrome phase II, Dec. 4-7, 2004;
  • Atherogenics (AGIX): AGI-1067, atherosclerosis, end of 2004;
  • Pharmos (PARS): Dexanabinol, traumatic brain injury phase III, end of 2004;
  • Aphton (APHT): Insegia, gastrointestinal cancer phase III, end of 2004;
  • Isis Pharmaceuticals (ISIS): Alifacorsen, Crohn's disease phase III, ulcerative colitis phase II, end of 2004;
  • Corgentech (CGTK): E2F Decoy, peripheral bypass graft failure phase III, late fourth quarter 2004; E2F Decoy, coronary artery bypass graft failure phase III, early 2005;
  • Cell Therapeutics (CTIC): Xyotax, nonsmall cell lung cancer phase III, first quarter 2005;
  • Axonyx (AXYX): Phenserine, Alzheimer's disease, phase II, first quarter 2005;
  • Encysive Pharmaceuticals (ENCY): Thelin, pulmonary arterial hypertension phase III, February 2005;
  • Onyx Pharmaceuticals (ONXX): BAY 43-9006, renal cancer phase III interim analysis, first half 2005.
  • Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. He invites you to send your feedback to

    Select the service that is right for you!

    Action Alerts PLUS
    Try it NOW

    Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

    Product Features:
    • $2.5+ million portfolio
    • Large-cap and dividend focus
    • Intraday trade alerts from Cramer
    • Weekly roundups
    TheStreet Quant Ratings
    Try it NOW
    Only $49.95/yr

    Access the tool that DOMINATES the Russell 2000 and the S&P 500.

    Product Features:
    • Buy, hold, or sell recommendations for over 4,300 stocks
    • Unlimited research reports on your favorite stocks
    • A custom stock screener
    • Upgrade/downgrade alerts
    Stocks Under $10
    Try it NOW

    David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

    Product Features:
    • Model portfolio
    • Stocks trading below $10
    • Intraday trade alerts
    • Weekly roundups
    Dividend Stock Advisor
    Try it NOW

    Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

    Product Features:
    • Diversified model portfolio of dividend stocks
    • Alerts when market news affect the portfolio
    • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
    Real Money Pro
    Try it NOW

    All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

    Product Features:
    • Real Money + Doug Kass Plus 15 more Wall Street Pros
    • Intraday commentary & news
    • Ultra-actionable trading ideas
    Options Profits
    Try it NOW

    Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

    Product Features:
    • 100+ monthly options trading ideas
    • Actionable options commentary & news
    • Real-time trading community
    • Options TV
    To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
    Submit an article to us!


    DOW 18,053.71 +23.50 0.13%
    S&P 500 2,088.77 +6.89 0.33%
    NASDAQ 4,806.8590 +33.3870 0.70%

    Brokerage Partners

    Rates from

    • Mortgage
    • Credit Cards
    • Auto

    Free Newsletters from TheStreet

    My Subscriptions:

    After the Bell

    Before the Bell

    Booyah! Newsletter

    Midday Bell

    TheStreet Top 10 Stories

    Winners & Losers

    Register for Newsletters
    Top Rated Stocks Top Rated Funds Top Rated ETFs